RxDoctor Payments Data

Katherine Peters

Neurology · Durham, NCNPI 1689728214

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $29,406 of the $39,165 with a category attached, or 75.1%. 17 manufacturers reported payments, led by Servier Pharmaceuticals LLC at 45.9% of the total. Reporting peaked in 2024 at $9,935 and has fallen 97.5% since, to $244 in 2025.

$39,165in general payments, 2019–2025

Across 38 payments — averaging $1030.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Servier Pharmaceuticals LLC$18K
  • Eisai CO., LTD.$6K
  • Bayer$6K
  • Biogen$3K
  • Telix Pharmaceuticals$3K
  • Blue Earth Diagnostics$1K
  • plus $3K from 11 others
$10,964,584in research payments, 2019–2025

Across 929 payments — averaging $11,803 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Servier Bioinnovation$8.3M
  • Servier Pharmaceuticals LLC$1.7M
  • Merck$392K
  • Agios Pharmaceuticals, Inc.$278K
  • Tersera Therapeutics LLC$121K
  • Siemens Medical Solutions USA, Inc.$102K
  • plus $143K from 5 others

What the payments were for

  • Consulting fees$29,40675%
  • Speaking & faculty fees$6,08316%
  • Travel & lodging$6672%
  • Food & beverage$3,0098%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,165 in reported general payments places this provider in the 85th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$22,189
Medicare patients
76
Services billed
252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TibsovoIvosidenib17$491,983

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Servier Pharmaceuticals LLCTibsovo$17,979$491,98317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 566 neurology providers in North Carolina.

Other neurology in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →